Chemotherapy may be more effective in highly proliferative ovarian carcinomas-A translational research subprotocol of a prospective randomized phase III study (AGO-OVAR 3 protocol)

Gynecologic Oncology

Volumn 103, Issue 1, 2006, Pages 67-71

  Kommoss, Stefan ^a   du Bois, Andreas ^b   Schmidt, Dietmar ^a   Parwaresch, R ^c   Pfisterer, Jacobus ^c   Kommoss, Friedrich ^a  

^a Institute of Pathology   (Germany)

^b DR HORST SCHMIDT KLINIKEN   (Germany)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Chemotherapy; Immunohistochemistry; Ki 67; Ki S2; Ki S5; Ovarian carcinoma; Prognosis; Proliferative activity

Indexed keywords

KI 67 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY KI S2; MONOCLONAL ANTIBODY KI S5; PACLITAXEL; PLATINUM; UNCLASSIFIED DRUG;

ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CELL PROLIFERATION; CHEMOSENSITIVITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS;

AGED; ANTIBODIES, MONOCLONAL; CELL GROWTH PROCESSES; CLINICAL TRIALS, PHASE II; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; PARAFFIN EMBEDDING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS;

EID: 33748676715     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.01.037     Document Type: Article

References (24)

1. Rudolph P., Alm P., Heidebrecht H.J., et al. Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer. J. Natl. Cancer Inst. 91 (1999) 271-278
2. Bohm J., Koch S., Gais P., et al. Prognostic value of MIB-1 in neuroendocrine tumours of the lung. J. Pathol. 178 (1996) 402-409
3. Rudolph P., Schubert C., Schubert B., et al. Proliferation marker Ki-S5 as a diagnostic tool in melanocytic lesions. J. Am. Acad. Dermatol. 37 (1997) 169-178
4. Gerdes J., Lemke H., Baisch H., et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J. Immunol. 133 (1984) 1710-1715
5. Kreipe H., Wacker H.H., Heidebrecht H.J., et al. Determination of the growth fraction in non-Hodgkin's lymphomas by monoclonal antibody Ki-S5 directed against a formalin-resistant epitope of the Ki-67 antigen. Am. J. Pathol. 142 (1993) 1689-1694
6. Heidebrecht H.J., Buck F., Steinmann J., et al. p100: a novel proliferation-associated nuclear protein specifically restricted to cell cycle phases S, G2, and M. Blood 90 (1997) 226-233
7. du Bois A., Luck H.J., Meier W., et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J. Natl. Cancer Inst. 95 (2003) 1320-1329
8. Scully R.E. World Health Organization International Histological Classification of Tumours-Histological typing of ovarian tumours. 2nd ed. (1999), Springer Verlag, Berlin
9. In: Tavassoli F.A., and Devi lee P. (Eds). World Health Organization classification of tumours. Pathology and genetics of tumours of the breast and female genital organs (2003), IARC Press, Lyon
10. Norton A.J., Jordan S., and Yeomans P. Brief, high-temperature heat denaturation (pressure cooking): a simple and effective method of antigen retrieval for routinely processed tissues. J. Pathol. 173 (1994) 371-379
11. Guesdon J.L., Ternynck T., and Avrameas S. The use of avidin-biotin interaction in immunoenzymatic techniques. J. Histochem. Cytochem. 27 (1979) 1131-1139
12. Cordell J.L., Falini B., Erber W.N., et al. Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J. Histochem. Cytochem. 32 (1984) 219-229
13. Armitage P., and Berry G. Statistical methods in medical research. 3rd ed. (1994), Blackwell, Oxford
14. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53 (1958) 457-481
15. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother. Rep. 50 (1966) 163-170
16. Cox D.R. Regression models and life tables. J. R. Stat. Soc. B34 (1972) 187-202
17. Layfield L.J., Saria E.A., Berchuck A., et al. Prognostic value of MIB-1 in advanced ovarian carcinoma as determined using automated immunohistochemistry and quantitative image analysis. J. Surg. Oncol. 66 (1997) 230-236 [discussion 236-7]
18. Khalifeh I., Munkarah A.R., Schimp V., et al. The impact of C-kit and Ki-67 expression on patients prognosis in advanced ovarian serous carcinoma. Int. J. Gynecol. Pathol. 24 (2005) 228-234
19. Garzetti G.G., Ciavattini A., Goteri G., et al. Ki67 antigen immunostaining (MIB 1 monoclonal antibody) in serous ovarian tumors: index of proliferative activity with prognostic significance. Gynecol. Oncol. 56 (1995) 169-174
20. Mita S., Nakai A., Maeda S., et al. Prognostic significance of Ki-67 antigen immunostaining (MIB-1 monoclonal antibody) in ovarian cancer. J. Nippon Med. Sch. 71 (2004) 384-391
21. Isola J., Kallioniemi O.P., Korte J.M., et al. Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: correlation with DNA flow cytometry, biochemical receptor assay, and patient survival. J. Pathol. 162 (1990) 295-301
22. Wong W.S., and Tattersall M.H. Immunohistochemical determination of tumour growth fraction in human ovarian carcinoma. Br. J. Obstet. Gynaecol. 96 (1989) 720-724
23. McCormack E.S., Borzillo G.V., Ambrosino C., et al. Transforming growth factor beta-3 protection of epithelial cells from cycle selective chemotherapy in vitro. Biochem. Pharmacol. 53 (1997) 1149-1159
24. Rowinsky E.K., Cazenave L.A., and Donehower R.C. Taxol: a novel investigational antimicrotubule agent. J. Natl. Cancer Inst. 82 (1990) 1247-1259